Digital Health Trial: Can Artificial Intelligence Predict the Optimal Supplements for Crohn 's Disease and Ulcerative Colitis?
The two most common types of IBD are Crohn 's Disease and Ulcerative Colitis. Each have some similar elements but are unique as well. Treating IBD can require both medications and surgery, but dietary changes and supplements can also play an important role.
Some people may follow specific diets for Crohn 's Disease or Ulcerative Colitis, but there are still many unknowns about what works best for individuals.
Supplements also play an important role in helping individuals manage their Crohn 's or Colitis. These can range from probiotics, to teas, to different herbal compounds, a large number of possibilities making it hard to know what works. Another challenge is that one supplement type may actually be made up of several active ingredients and it can be hard to understand how all of these work together. IBD is complex and we are still uncovering new information, such as the role of the gut microbiome. Gut microbes (bacteria) help us digest foods and supplements but If the digestive tract is damaged, however, it may lead to the growth of different types of microbes so it is a very complex picture.
Understanding the relationships between different supplements and microbes with IBD is a big data challenge that artificial intelligence (AI) is great for. AI can help find patterns through very large volumes of data that we have not been able to do until very recently. This digital health trial is the first framework for establishing how AI can help predict which supplements may be optimal for people suffering with inflammatory bowel disease, a chronic condition with no easy answers.
By collecting data points around the disease and especially the relationship between supplements, gut microbiome and other “omics” like environment or physical activity and applying artificial intelligence (AI) technology to the data, there is a chance to identify common patterns among those correlations and gain deeper insights on the disease.